Thiotepa
Active ingredient: Thiotepa
In short: Thiotepa for Injection is indicated for treatment of adenocarcinoma of the breast or ovary. Thiotepa for Injection is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.
What is Thiotepa used for?
Thiotepa for Injection is indicated for treatment of adenocarcinoma of the breast or ovary.
Thiotepa for Injection is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.
Thiotepa for Injection is indicated for treatment of superficial papillary carcinoma of the urinary bladder.
Pediatric use information is approved for Adienne SA’s TEPADINA (thiotepa) for injection. However, due to Adienne SA’s marketing exclusivity rights, the drug product is not labeled with that information.
âš Boxed warning (FDA's strongest warning)
WARNING: SEVERE MYELOSUPPRESSION, CARCINOGENICITY
Thiotepa may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation (HSCT) is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of thiotepa .
Thiotepa should be considered potentially carcinogenic in humans .
Thiotepa dosage
Adenocarcinoma of the Breast or Ovary
The recommended dose of thiotepa for injection for treatment of adenocarcinoma of the breast or ovary is 0.3 to 0.4 mg/kg intravenously. Doses should be given at 1 to 4 week intervals. Initially the higher dose in the given range is commonly administered. The maintenance dose should be adjusted weekly on the basis of pretreatment control blood counts and subsequent blood counts. Maintenance doses should not be administered more frequently than weekly.
Malignant Effusions
The recommended dose of thiotepa for injection for treatment of malignant effusions is 0.6 to 0.8 mg/kg intracavitary. Administration is usually effected through the same tubing which is used to remove the fluid from the cavity involved. Doses should be given at 1 to 4 week intervals. Initially the higher dose in the given range is commonly administered. The maintenance dose should be adjusted weekly on the basis of pretreatment control blood counts and subsequent blood counts. Maintenance doses should not be administered more frequently than weekly.
Superficial Papillary Carcinoma of the Urinary Bladder
The recommended dose of thiotepa for injection for treatment of superficial papillary carcinoma of the urinary bladder is 60 mg in 30 to 60 mL of Sodium Chloride Injection into the bladder by catheter. The solution should be retained for 2 hours. If the patient finds it impossible to retain 60 mL for 2 hours, the dose may be given in a volume of 30 mL. The patient may be repositioned every 15 minutes for maximum area contact. The usual course of treatment is once a week for 4 weeks. The course may be repeated if necessary, but second and third courses must be given with caution since bone-marrow depression may be increased.
Pediatric use information is approved for Adienne SA’s TEPADINA (thiotepa) for injection. However, due to Adienne SA’s marketing exclusivity rights, the drug product is not labeled with that information.
Thiotepa for injection is a cytotoxic drug. Follow applicable special handling and disposal procedures1.
Reconstitution
Reconstitute thiotepa for injection 15 mg with 1.5 mL of sterile water for injection. Using a syringe fitted with a needle, aseptically withdraw 1.5 mL of sterile water for injection. Inject the content of the syringe into the vial through the rubber stopper. Remove the syringe and needle, and mix manually by repeated inversions.
Reconstitute thiotepa for injection 100 mg with 10 mL of sterile water for injection. Using a syringe fitted with a needle, aseptically withdraw 10 mL of sterile water for injection. Inject the content of the syringe into the vial through the rubber stopper. Remove the syringe and needle, and mix manually by repeated inversions. …
How to take Thiotepa — instructions & advice from the label
Hypersensitivity
Counsel patients on the signs and symptoms of hypersensitivity and to seek immediate emergency assistance if they develop any of these signs and symptoms .
Myelosuppression
Inform patients of the possibility of developing low blood cell counts and the need for hematopoietic progenitor cell infusion. Instruct patients to immediately report to their healthcare provider if bleeding or fever occurs .
Females and Males of Reproductive Potential
Thiotepa can cause fetal harm. Advise females receiving thiotepa to avoid pregnancy during thiotepa treatment and for at least 6 months after the final dose of thiotepa .
Advise males with female sexual partners of reproductive potential to use effective contraception during thiotepa treatment and for at least 1 year after the final dose of thiotepa .
Advise females to report pregnancy immediately .
Advise patients that thiotepa can produce infertility. Inform male patients about the possibility of sperm conservation before the start of therapy .
Lactation
Advise patients to avoid breastfeeding while receiving thiotepa .
Secondary malignancies
Inform patients that thiotepa can increase the risk of secondary malignancy . …
Warnings & precautions
Do not take this medicine if: Thiotepa is contraindicated in:
Patients with severe hypersensitivity to thiotepa
Concomitant use with live or attenuated vaccines
The consequence of treatment with high doses of thiotepa together with other chemotherapy is profound myelosuppression occurring in all patients. Monitor complete blood counts, and provide supportive care for infections, anemia and thrombocytopenia until there is adequate hematopoietic recovery.
For patients receiving thiotepa for treatment of adenocarcinoma of the breast, adenocarcinoma of the ovary, malignant effusions and superficial papillary carcinoma of the urinary bladder, if the bone marrow has been compromised by prior irradiation or chemotherapy, or is recovering from chemotherapy, the risk of severe myelosuppression with thiotepa may be increased. Perform periodic complete blood counts during the course of treatment with thiotepa. Provide supportive care for infections, bleeding, and symptomatic anemia .
Pediatric use information is approved for Adienne SA’s TEPADINA (thiotepa) for injection. However, due to Adienne SA’s marketing exclusivity rights, the drug product is not labeled with that information.
Clinically significant hypersensitivity reactions, including anaphylaxis, have occurred following administration of thiotepa. If anaphylactic or other clinically significant allergic reaction occurs, discontinue treatment with thiotepa, initiate appropriate therapy, and monitor until signs and symptoms resolve .
Thiotepa and/or its active metabolites may be excreted in part via skin patients receiving high-dose therapy. Treatment with thiotepa may cause skin discoloration, pruritus, blistering, desquamation, and peeling that may be more severe in the groin, axillae, skin folds, in the neck area, and under dressings. …
Thiotepa side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Myelosuppression
Infection
Hypersensitivity
Cutaneous Toxicity
Hepatic Veno-Occlusive Disease
Central Nervous System Toxicity
Carcinogenicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions with Treatment of adenocarcinoma of the breast, adenocarcinoma of the ovary, malignant effusions and superficial papillary carcinoma of the urinary bladder
Gastrointestinal: Nausea, vomiting, abdominal pain, anorexia.
General: Fatigue, weakness. Febrile reaction and discharge from a subcutaneous lesion may occur as the result of breakdown of tumor tissue.
Hypersensitivity Reactions: Allergic reactions - rash, urticaria, laryngeal edema, asthma, anaphylactic shock, wheezing.
Local Reactions: Contact dermatitis, pain at the injection site.
Neurologic: Dizziness, headache, blurred vision.
Renal: Dysuria, urinary retention, chemical cystitis or hemorrhagic cystitis.
Reproductive: Amenorrhea, interference with spermatogenesis.
Respiratory: Prolonged apnea has been reported when succinylcholine was administered prior to surgery, following combined use of thiotepa and other anticancer agents. …
Drug interactions
In vitro studies suggest that thiotepa is metabolized by CYP3A4 and CYP2B6 to its active metabolite TEPA. Avoid coadministration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with thiotepa due to the potential effects on efficacy and toxicity . Consider alternative medications with no or minimal potential to inhibit or induce CYP3A4. If concomitant use of strong CYP3A4 modulators cannot be avoided, closely monitor for adverse drug reactions.
In vitro studies suggest that thiotepa inhibits CYP2B6. Thiotepa may increase the exposure of drugs that are substrates of CYP2B6 in patients; however, the clinical relevance of this in vitro interaction is unknown .
The administration of thiotepa with cyclophosphamide in patients reduces the conversion of cyclophosphamide to the active metabolite, 4-hydroxycyclophosphamide; the effect appears sequence dependent with a greater reduction in the conversion to 4-hydroxycyclophosphamide when thiotepa is administered 1.5 hours prior to the intravenous administration of cyclophosphamide compared to administration of thiotepa after intravenous cyclophosphamide . …
About this medicine
Thiotepa for Injection, USP is an alkylating agent. Thiotepa for Injection, USP is supplied as a nonpyrogenic, sterile, white lyophilized powder or lyophilized cake for intravenous, intracavitary, or intravesical use after reconstitution and dilution.
Thiotepa for Injection, USP is available in a single-dose vial containing:
15 mg thiotepa. After reconstitution with 1.5 mL of water for injection, each mL contains 10 mg thiotepa.
100 mg thiotepa. After reconstitution with 10 mL of water for injection, each mL contains 10 mg thiotepa.
Thiotepa is a synthetic product with antitumor activity. The chemical name for thiotepa is Tris(1-aziridinyl)phosphine sulfide. Thiotepa has the following structural formula:
Thiotepa has the molecular formula C
6
H
12
N
3
PS, and a molecular weight of 189.22, and it appears as fine, white crystalline flakes, with a melting range of 52° to 57°C. It is soluble in water and organic solvents. When reconstituted with sterile water for injection, the resulting solution has a pH of approximately 5.5 to 7.5. Thiotepa is unstable in acid medium. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4b4725eb-95f1-45cc-852f-152beb5f1e2c. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate